Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ALG-010133

Other · developed by Aligos Therapeutics

Phase 1 Most advanced trial (none active)

ALGS Developer

1 Registered trials

What is ALG-010133?

ALG-010133 is an agent studied in chronic hepatitis B, given as single or multiple doses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Infectious disease
Developer: Aligos Therapeutics (ALGS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04485663	Phase 1	Chronic Hepatitis B	Terminated	ALGS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis B

More from Aligos Therapeutics

ALG-020572 Phase 1 ALG-055009 Phase 2 ALG-097558 Phase 1 ALG-125755 Phase 1 Pevifoscorvir Phase 2

Sources

ClinicalTrials.gov NCT04485663

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALGS page.

Follow ALGS, the company behind ALG-010133

See ALGS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALGS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z